September 23, 2019
Cerevel Therapeutics happy with results from a Phase 2 study of Tavapadon in patients with early-stage Parkinson’s Disease
Cerevel’s study of Tavapadon results demonstrated a statistically significant improvement in motor symptoms with once-daily dosing of oral tavapadon, which has enabled the company to plan on kicking off Phase 3 trials of tavapadon to fully characterize its potential benefit for patients with Parkinson’s disease.